Atreca bags $35M B round for next-gen immuno-oncology drug pipeline
Atreca out of Redwood City, CA has rounded up a $35 million B round to fund its research on the human immune system and how it can be better aroused against cancer by the right kind of antibodies.
The biotech is taking a next-gen approach to immuno-oncology, part of a rapidly broadening field that are learning why the first generation of checkpoint inhibitors often don’t work for more than a minority of any particular patient group. By analyzing active B cell responses to tumor tissue, they expect to find multiple new and more effective drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
